This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by McKenna, C. J. Articles by Schwartz, R. S. Search for Related Content PubMed PubMed Citation Articles by McKenna, C. J. Articles by Schwartz, R. S.

(Circulation. 1998;97:2551-2556.)
© 1998 American Heart Association, Inc.

Basic Science Reports

Selective ET_A Receptor Antagonism Reduces Neointimal Hyperplasia in a Porcine Coronary Stent Model

Charles J. McKenna, MB, MRCP; Sandra E. Burke, PhD; Terry J. Opgenorth, PhD; Robert J. Padley, PhD; LaDonna J. Camrud, RN; Allan R. Camrud, RN; Jodi Johnson; Paula J. Carlson, BS; Amir Lerman, MD; David R. Holmes, Jr, MD; ; Robert S. Schwartz, MD

From the Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minn, and Abbott Laboratories, Abbott Park, Ill (S.E.B., T.J.O., R.J.P.).

Correspondence to Robert S. Schwartz, MD, Division of Cardiovascular Diseases, SMH 4523, Rochester, MN 55905.

Background—As endothelin binds to ET_A receptors, it stimulates vascular smooth muscle cell proliferation and may thus be pivotally involved in the pathogenesis of restenosis. This study assessed the ability of a potent and selective ET_A antagonist to reduce neointimal hyperplasia in a porcine coronary artery stented injury model.

Methods and Results—Fifty-five pigs were randomized to receive placebo or the oral ET_A-selective antagonist ABT147627 twice daily for 28 days in one of three doses: 0.75 mg/kg (low), 3.75 mg/kg (mid), and 10.0 mg/kg (high). Each underwent oversized stent deployment in two randomly assigned major epicardial coronary arteries. Three animals (5.5%) died as a consequence of stent thrombosis within 24 hours of the procedure. The remaining 52 animals (13 pigs per group) survived without complication until predetermined euthanasia at 28 days. In the placebo group, mean injury score was 1.73±0.80, with a mean neointimal response of 0.45±0.24 mm. By comparison, the low-dose group had a similar mean injury score of 1.79±0.75 with reduced neointimal response, 0.36±0.22 mm (P<0.01). Mean injury score in the mid-dose animals was significantly greater than in the placebo group (1.94±0.92; P<0.05). The neointimal hyperplasia associated with this injury was less than with placebo, although the difference did not reach statistical significance (0.40±0.25 mm; P=0.05). In the high-dose pigs, mean injury score was also significantly greater than in the placebo arm (1.93±0.73; P<0.05). Despite this, neointimal response was also significantly less (0.37±0.37 mm; P<0.01).

Conclusions—Oral, selective ET_A receptor antagonism significantly reduced neointimal hyperplasia forming over porcine coronary stented injuries in the first 28 days. This strategy may have clinical potential for the limitation and treatment of coronary restenosis after percutaneous revascularization.

Key Words: endothelin • angioplasty • restenosis

This article has been cited by other articles:

				D. W. Anggrahini, N. Emoto, K. Nakayama, B. Widyantoro, S. Adiarto, N. Iwasa, H. Nonaka, Y. Rikitake, Y. Y. Kisanuki, M. Yanagisawa, et al. Vascular endothelial cell-derived endothelin-1 mediates vascular inflammation and neointima formation following blood flow cessation Cardiovasc Res, April 1, 2009; 82(1): 143 - 151. [Abstract] [Full Text] [PDF]

				R. J Russo, P. D Silva, and M. Yeager Coronary artery overexpansion increases neointimal hyperplasia after stent placement in a porcine model Heart, December 1, 2007; 93(12): 1609 - 1615. [Abstract] [Full Text] [PDF]

				M. Gossl and A. Lerman Endothelin: Beyond a Vasoconstrictor Circulation, March 7, 2006; 113(9): 1156 - 1158. [Full Text] [PDF]

				S. Chen, Y. Qiong, and D. G. Gardner A Role for p38 Mitogen-Activated Protein Kinase and c-Myc in Endothelin-Dependent Rat Aortic Smooth Muscle Cell Proliferation Hypertension, February 1, 2006; 47(2): 252 - 258. [Abstract] [Full Text] [PDF]

				A. G. Touchard and R. S. Schwartz Preclinical Restenosis Models: Challenges and Successes Toxicol Pathol, January 1, 2006; 34(1): 11 - 18. [Abstract] [Full Text] [PDF]

				J. Rodriguez-Vita, M. Ruiz-Ortega, M. Ruperez, V. Esteban, E. Sanchez-Lopez, J. J. Plaza, and J. Egido Endothelin-1, via ETA Receptor and Independently of Transforming Growth Factor-{beta}, Increases the Connective Tissue Growth Factor in Vascular Smooth Muscle Cells Circ. Res., July 22, 2005; 97(2): 125 - 134. [Abstract] [Full Text] [PDF]

				A. Lerman Restenosis: Another "Dysfunction" of the Endothelium Circulation, January 4, 2005; 111(1): 8 - 10. [Full Text] [PDF]

				Y. Matsumoto, T. Uwatoku, K. Oi, K. Abe, T. Hattori, K. Morishige, Y. Eto, Y. Fukumoto, K.-i. Nakamura, Y. Shibata, et al. Long-Term Inhibition of Rho-Kinase Suppresses Neointimal Formation After Stent Implantation in Porcine Coronary Arteries: Involvement of Multiple Mechanisms Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 181 - 186. [Abstract] [Full Text] [PDF]

				N. Murakoshi, T. Miyauchi, Y. Kakinuma, T. Ohuchi, K. Goto, M. Yanagisawa, and I. Yamaguchi Vascular Endothelin-B Receptor System In Vivo Plays a Favorable Inhibitory Role in Vascular Remodeling After Injury Revealed by Endothelin-B Receptor-Knockout Mice Circulation, October 8, 2002; 106(15): 1991 - 1998. [Abstract] [Full Text] [PDF]

				J. Meding, L. M. Dinkelborg, M. K. Grieshaber, and W. Semmler Targeting of Endothelin Receptors for Molecular Imaging of Atherosclerosis in Rabbits J. Nucl. Med., March 1, 2002; 43(3): 400 - 405. [Abstract] [Full Text] [PDF]

				A. B. Buchwald, A. H. Wagner, C. Webel, and M. Hecker Decoy oligodeoxynucleotide againstactivator protein-1 reducesneointimal proliferation after coronaryangioplasty in hypercholesterolemic minipigs J. Am. Coll. Cardiol., February 20, 2002; 39(4): 732 - 738. [Abstract] [Full Text] [PDF]

				A. W Barolet, S. Babaei, R. Robinson, P. Picard, W. Tsui, N. Nili, F. Mohamed, O. Ornatsky, J. D Sparkes, D. J Stewart, et al. Administration of exogenous endothelin-1 following vascular balloon injury: early and late effects on intimal hyperplasia Cardiovasc Res, December 1, 2001; 52(3): 468 - 476. [Abstract] [Full Text] [PDF]

				A. Bayes-Genis, A. R. Camrud, M. Jorgenson, J. Donovan, K. L. Shogren, D. R. Holmes Jr, and R. S. Schwartz Pressure rinsing of coronary stents immediately before implantation reduces inflammation and neointimal hyperplasia J. Am. Coll. Cardiol., August 1, 2001; 38(2): 562 - 568. [Abstract] [Full Text] [PDF]

				W. R. Huckle, M. D. Drag, W. R. Acker, M. Powers, R. C. McFall, D. J. Holder, T. F. Walsh, R. S. Schwartz, W. J. Greenlee, and R. G. Johnson Jr Effects of L-749,329, an ETA/ETB Endothelin Receptor Antagonist, in a Porcine Coronary Artery Injury Model of Vascular Restenosis Circulation, April 10, 2001; 103(14): 1899 - 1905. [Abstract] [Full Text] [PDF]

				C. B. Taner, S. R. Severson, P. J. M. Best, A. Lerman, and V. M. Miller Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia J Appl Physiol, March 1, 2001; 90(3): 816 - 820. [Abstract] [Full Text] [PDF]

				P. A. MacCarthy, N. C. Pegge, B. D. Prendergast, A. M. Shah, and P. H. Groves The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone J. Am. Coll. Cardiol., January 1, 2001; 37(1): 137 - 143. [Abstract] [Full Text] [PDF]

				T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]

				R. Hoffmann and G.S. Mintz Coronary in-stent restenosis--predictors, treatment and prevention Eur. Heart J., November 1, 2000; 21(21): 1739 - 1749. [PDF]

				B. J. F. Hill, L. C. Katwa, B. R. Wamhoff, and M. Sturek Enhanced EndothelinA Receptor-Mediated Calcium Mobilization and Contraction in Organ Cultured Porcine Coronary Arteries J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 484 - 491. [Abstract] [Full Text]

				K. Peppel, A. Jacobson, X. Huang, J. P. Murray, M. Oppermann, and N. J. Freedman Overexpression of G Protein-Coupled Receptor Kinase-2 in Smooth Muscle Cells Attenuates Mitogenic Signaling via G Protein-Coupled and Platelet-Derived Growth Factor Receptors Circulation, August 15, 2000; 102(7): 793 - 799. [Abstract] [Full Text] [PDF]

				P. J. M. Best, L. O. Lerman, J. C. Romero, D. Richardson, D. R. Holmes Jr, and A. Lerman Coronary Endothelial Function Is Preserved With Chronic Endothelin Receptor Antagonism in Experimental Hypercholesterolemia In Vitro Arterioscler Thromb Vasc Biol, November 1, 1999; 19(11): 2769 - 2775. [Abstract] [Full Text] [PDF]

				M. R Dashwood, P. Noertersheuser, M. Kirchengast, and K. Munter Altered endothelin-1 binding following balloon angioplasty of pig coronary arteries: effect of the ETA receptor antagonist, LU 135252 Cardiovasc Res, August 1, 1999; 43(2): 445 - 456. [Abstract] [Full Text] [PDF]

				Z. Yang, N. Krasnici, and T. F. Luscher Endothelin-1 Potentiates Human Smooth Muscle Cell Growth to PDGF : Effects of ETA and ETB Receptor Blockade Circulation, July 6, 1999; 100(1): 5 - 8. [Abstract] [Full Text] [PDF]

				P. J. M. Best, C. J. McKenna, D. Hasdai, D. R. Holmes Jr, and A. Lerman Chronic Endothelin Receptor Antagonism Preserves Coronary Endothelial Function in Experimental Hypercholesterolemia Circulation, April 6, 1999; 99(13): 1747 - 1752. [Abstract] [Full Text] [PDF]